These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35872093)

  • 21. Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease.
    Fortis S; Comellas A; Make BJ; Hersh CP; Bodduluri S; Georgopoulos D; Kim V; Criner GJ; Dransfield MT; Bhatt SP;
    Ann Am Thorac Soc; 2019 Jul; 16(7):826-835. PubMed ID: 30908927
    [No Abstract]   [Full Text] [Related]  

  • 22. [Community-acquired pneumonia in patients with chronic obstructive pulmonary disease treated with inhaled corticosteroids or other bronchodilators. Study PNEUMOCORT].
    Morros R; Vedia C; Giner-Soriano M; Casellas A; Amado E; Baena JM;
    Aten Primaria; 2019; 51(6):333-340. PubMed ID: 29661670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of chronic obstructive pulmonary disease: A review focusing on exacerbations.
    Bollmeier SG; Hartmann AP
    Am J Health Syst Pharm; 2020 Feb; 77(4):259-268. PubMed ID: 31930287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of exacerbations of COPD with pharmacotherapy.
    Miravitlles M
    Eur Respir Rev; 2010 Jun; 19(116):119-26. PubMed ID: 20956180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapies for COPD Exacerbations in Adults.
    Saguil A
    Am Fam Physician; 2020 May; 101(9):557-559. PubMed ID: 32352728
    [No Abstract]   [Full Text] [Related]  

  • 26. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
    Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
    Wedzicha JA; Decramer M; Ficker JH; Niewoehner DE; Sandström T; Taylor AF; D'Andrea P; Arrasate C; Chen H; Banerji D
    Lancet Respir Med; 2013 May; 1(3):199-209. PubMed ID: 24429126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis, Prevention and Treatment of Stable COPD and Acute Exacerbations of COPD: The Swiss Recommendations 2018.
    Stolz D; Barandun J; Borer H; Bridevaux PO; Brun P; Brutsche M; Clarenbach C; Eich C; Fiechter R; Frey M; Geiser T; Grob M; Helfenstein E; Junker L; Kohler M; Latshang T; Lechmann A; Maurer M; Nicod L; Quadri F; Schilter D; Sigrist T; Soccal P; Tarr P; Thurnheer R; Turk A; Tamm M
    Respiration; 2018; 96(4):382-398. PubMed ID: 30138943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
    Oba Y; Keeney E; Ghatehorde N; Dias S
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical inquiries: When are antibiotics indicated for acute COPD exacerbations?
    Balser E; Neher JO; Safranek S; Taraday J
    J Fam Pract; 2006 Dec; 55(12):1079-80. PubMed ID: 17137546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for Preventing COPD Exacerbations.
    Yawn B
    J Fam Pract; 2020 Sep; 69(7 Suppl):S75-S80. PubMed ID: 33104112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use and outcomes associated with long-acting bronchodilators among patients hospitalized for chronic obstructive pulmonary disease.
    Lindenauer PK; Shieh MS; Pekow PS; Stefan MS
    Ann Am Thorac Soc; 2014 Oct; 11(8):1186-94. PubMed ID: 25167078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD.
    Calverley PM; Anzueto AR; Dusser D; Mueller A; Metzdorf N; Wise RA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1297-1308. PubMed ID: 29719385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic Management of COPD Exacerbations: A Clinical Practice Guideline from the AAFP.
    Stevermer JJ; Fisher L; Lin KW; Liu R; Goodenberger D; Schellhase K; Vaughan B; Bird MD
    Am Fam Physician; 2021 Jul; 104(1):Online. PubMed ID: 34264593
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review.
    Hurst JR; Han MK; Singh B; Sharma S; Kaur G; de Nigris E; Holmgren U; Siddiqui MK
    Respir Res; 2022 Aug; 23(1):213. PubMed ID: 35999538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry.
    Kobayashi S; Hanagama M; Ishida M; Sato H; Ono M; Yamanda S; Yamada M; Aizawa H; Yanai M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3947-3955. PubMed ID: 30584294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship Between the GesEPOC 2021 Classification of Risk Levels and Phenotypes and the Incidence of Adverse Events.
    Golpe R; Figueira-Gonçalves JM; Esteban C; Amado-Diago CA; Aramburu A; García-Talavera I; Veiga I
    Arch Bronconeumol; 2022 May; 58(5):451-453. PubMed ID: 35312502
    [No Abstract]   [Full Text] [Related]  

  • 38. Mechanisms of Chronic Obstructive Pulmonary Disease Exacerbations.
    Wedzicha JA
    Ann Am Thorac Soc; 2015 Nov; 12 Suppl 2():S157-9. PubMed ID: 26595732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COPD exacerbation frequency and its association with health care resource utilization and costs.
    Dhamane AD; Moretz C; Zhou Y; Burslem K; Saverno K; Jain G; Renda A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2609-18. PubMed ID: 26664109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.